Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
60.57
+1.73 (2.94%)
At close: May 22, 2026, 4:00 PM EDT
60.50
-0.07 (-0.12%)
After-hours: May 22, 2026, 7:50 PM EDT
Twist Bioscience Revenue
Twist Bioscience had revenue of $110.72M in the quarter ending March 31, 2026, with 19.31% growth. This brings the company's revenue in the last twelve months to $409.48M, up 17.77% year-over-year. In the fiscal year ending September 30, 2025, Twist Bioscience had annual revenue of $376.57M with 20.32% growth.
Revenue (ttm)
$409.48M
Revenue Growth
+17.77%
P/S Ratio
9.21
Revenue / Employee
$418,263
Employees
979
Market Cap
3.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 376.57M | 63.60M | 20.32% |
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | 54.39M | 28.96M | 113.89% |
| Sep 30, 2018 | 25.43M | 14.66M | 136.16% |
| Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
| Sep 30, 2016 | 2.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.10B |
| Charles River Laboratories International | 4.03B |
| Revvity | 2.90B |
| RadNet | 2.14B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.19B |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
TWST News
- 3 days ago - Twist Bioscience Transcript: Investor Day 2026 - Transcripts
- 3 days ago - Twist Bioscience Slides: FY 2026 - Filings
- 17 days ago - LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery - Business Wire
- 20 days ago - Twist Bioscience announces inducement grants under Nasdaq listing rule - TheFly
- 20 days ago - Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Twist Bioscience price target raised to $60 from $55 at Guggenheim - TheFly
- 20 days ago - Twist Bioscience price target raised to $65 from $50 at Baird - TheFly
- 20 days ago - Twist Bioscience upgraded to Outperform from Market Perform at Leerink - TheFly